- Investing Ideas
- Global Pharmaceuticals & Biotech Pure Equity Growth
Global Pharmaceuticals & Biotech Pure Equity Growth
Results
50
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
50 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: US$119.9b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
SKBH.F
US$50.16
7D
0%
1Y
n/a
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$111.8b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$479.40
7D
9.9%
1Y
37.0%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$111.8b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$479.40
7D
9.9%
1Y
37.0%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$111.8b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$479.40
7D
9.9%
1Y
37.0%
Krystal Biotech
Market Cap: €10.9b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
4KB
€320.00
7D
-0.9%
1Y
163.9%
Krystal Biotech
Market Cap: US$10.9b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$375.40
7D
1.0%
1Y
152.1%
Krystal Biotech
Market Cap: €10.9b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
4KB
€326.80
7D
0.06%
1Y
n/a
Krystal Biotech
Market Cap: €10.9b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
1KRYS
€320.30
7D
-2.2%
1Y
158.4%
Krystal Biotech
Market Cap: R$10.1b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
K1YS34
R$44.80
7D
0%
1Y
n/a
Corcept Therapeutics
Market Cap: US$10.1b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$92.94
7D
5.0%
1Y
31.1%
Corcept Therapeutics
Market Cap: €10.1b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
1CORT
€80.54
7D
1.4%
1Y
34.7%
Corcept Therapeutics
Market Cap: €10.1b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
HTD
€81.32
7D
8.1%
1Y
41.4%
Corcept Therapeutics
Market Cap: US$10.1b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
0I3Q
US$92.39
7D
3.2%
1Y
32.4%
Camurus
Market Cap: US$34.4b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMR.F
US$60.00
7D
-1.7%
1Y
n/a
Camurus
Market Cap: SEK 34.4b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMXS
SEK 564.00
7D
0%
1Y
n/a
Camurus
Market Cap: €33.2b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
7CA
€51.75
7D
2.1%
1Y
-13.5%
Camurus
Market Cap: SEK 33.2b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 558.50
7D
-3.2%
1Y
-16.5%
Camurus
Market Cap: SEK 33.2b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
0RD1
SEK 555.44
7D
-3.7%
1Y
-16.3%
BioArctic
Market Cap: SEK 28.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
0RV2
SEK 321.06
7D
-2.7%
1Y
73.2%
BioArctic
Market Cap: SEK 28.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 322.60
7D
-0.9%
1Y
77.1%
BioArctic
Market Cap: €28.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
B9A
€28.70
7D
-2.8%
1Y
76.7%
BioArctic
Market Cap: US$28.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BRCT.F
US$35.00
7D
0%
1Y
n/a
BioArctic
Market Cap: SEK 28.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOABS
SEK 328.70
7D
0%
1Y
n/a
Bonesupport Holding
Market Cap: US$15.3b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BOEU.F
US$21.40
7D
0%
1Y
-29.6%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 224.00
7D
6.7%
1Y
-22.5%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
0RQO
SEK 224.40
7D
8.2%
1Y
-21.8%
Bonesupport Holding
Market Cap: €14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
2B4
€20.78
7D
12.4%
1Y
-19.7%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEXS
SEK 229.60
7D
0%
1Y
-18.6%
Neuren Pharmaceuticals
Market Cap: €2.1b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NK9
€9.90
7D
-2.9%
1Y
34.7%
Neuren Pharmaceuticals
Market Cap: AU$2.1b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$16.74
7D
-5.2%
1Y
18.1%
Neuren Pharmaceuticals
Market Cap: AU$2.1b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$16.71
7D
-4.8%
1Y
17.9%
Neuren Pharmaceuticals
Market Cap: US$2.1b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NURP.F
US$13.46
7D
0%
1Y
49.7%
MedinCell
Market Cap: €1.0b
A clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France.
MEB
€27.66
7D
-1.4%
1Y
79.4%
MedinCell
Market Cap: €1.0b
A clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France.
0ACH
€28.38
7D
-2.5%
1Y
78.3%
MedinCell
Market Cap: €1.0b
A clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France.
MEDCL
€28.76
7D
-1.8%
1Y
80.9%
CARsgen Therapeutics Holdings
Market Cap: HK$8.8b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$14.80
7D
3.8%
1Y
-31.8%